The U.S. Food and Drug Administration (FDA) announced its approval of the Autus Size-Adjustable Valve on Thursday, October 1, 2026. This valve, developed by Autus Valve Technologies Inc., which was acquired by Edwards Lifesciences, is intended for pediatric patients requiring pulmonary valve replacement due to congenital heart defects. The Autus valve is the first heart valve approved by the FDA that can be expanded after surgical implantation to accommodate a child's growth.
Congenital heart defects are among the most common birth defects, affecting approximately one in every 100 births in the United States. Pulmonary valve abnormalities, such as stenosis (narrowing) or atresia (failure to form), restrict blood flow from the heart to the lungs. These conditions impact around 4,200 babies in the U.S. annually. While treatments can improve blood flow, some children develop significant pulmonary regurgitation, where blood leaks back through the pulmonary valve. This can weaken the right ventricle and necessitate pulmonary valve replacement as the child grows.
Traditionally, children with these conditions have faced numerous open-heart surgeries to replace outgrown valves. The Autus valve aims to mitigate this by allowing for post-surgical expansion using a minimally invasive balloon catheter procedure. The valve can be initially implanted at about 13 millimeters in diameter, suitable for a toddler or preschool-aged child, and then widened to up to 22 millimeters, comparable to an adult-sized pulmonary valve.
Another notable feature of the Autus valve is its use of polymeric material for its leaflets, the flaps that control blood flow. This marks the first time the FDA has approved a heart valve with polymeric leaflets for any indication. Traditional valves often use animal-derived tissue, which can harden and degrade more quickly in children, leading to earlier repeat surgeries. One-year follow-up data suggest the Autus valve's synthetic leaflets maintain their performance over time.
The FDA's approval followed a stringent premarket approval pathway, typically reserved for Class III medical devices that pose the highest risk. The decision was based on data from a clinical study involving 62 pediatric patients across 12 U.S. sites. At the six-month follow-up, 60 patients demonstrated acceptable hemodynamic performance, with blood flow through the right side of the heart within acceptable limits and no more than mild leakage. All patients in the study had successful implantations, with no reported deaths, blood clots, or strokes. While three patients experienced valve frame fractures and two had reduced leaflet movement, these events did not cause symptoms. Two patients whose valves began to deteriorate as they outgrew them had successful non-invasive expansions.
Dr. Michelle Tarver, director of the FDA's Center for Devices and Radiological Health, stated that the Autus valve offers doctors the option of fewer operating room visits, potentially improving the quality of life for children and their families. Dr. Emile Bacha, surgeon-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center and a trial investigator, noted that the valve provides congenital heart teams a new approach to long-term care planning. Patients in the ongoing study will be followed for 10 years to gather more long-term data on the valve's performance and the effectiveness of expansions.